FINWIRES · TerminalLIVE
FINWIRES

Semtech's AI Business Ramp Likely to Lift Fiscal Q1 Results, Oppenheimer Says

By

Semtech (SMTC) is likely to report "upside" to fiscal Q1 results and fiscal Q2 outlook as demand for its data center artificial intelligence business ramps up, Oppenheimer said in a report emailed Friday.

The brokerage said ramping deployments of active copper cables and linear pluggable optics with large cloud service providers, including what it believes is a deployment by Alphabet's (GOOG, GOOGL) Google, are driving growth.

Oppenheimer expects the ACC and LPO market to grow at a 90% compound annual growth rate through 2029, according to the report.

Semtech's "Infrastructure" segment, which accounts for 33% of revenue, is expected to rise 9% sequentially and 29% year over year, supported by "FiberEdge" products and increasing AI data center demand, the report said. The firm also pointed to "accelerating" demand for LoRa products in Semtech's Industrial segment as "multiprotocol" capabilities expand use cases in robotics, drones and automation.

Semtech has "identified a preferred buyer" for its SWIR cellular modules business, and a divestiture could immediately boost earnings per share and raise companywide gross margins to above 60% from just over 50%, Oppenheimer said.

Oppenheimer reiterated an outperform rating on Semtech and raised its price target to $150 from $110.

Price: $156.39, Change: $+9.86, Percent Change: +6.73%

Related Articles

Wire

DocuSign AI-Backed Platform Increasingly Addressing Enterprise Needs, RBC Says

DocuSign's (DOCU) AI-backed platform IAM, initially targeted at mid-market clients, is increasingly addressing enterprise needs, RBC Capital Markets said in a note emailed Friday after attending DocuSign's Momentum conference.RBC said that "enterprise remains early days" for the platform but value is acrruing as the company's clients "do more with the platform over time, and deeper role-specific use cases (sales, procurement, legal)" are on the rise.The IAM platform is seen as "creating more opportunity for partners to add value relative to the legacy e-signature business," the note said.RBC also highlighted that DocuSign is launching an AI assistant as well as autonomous agents that will be able to automate contract reviews, approval routing, and obligation tracking inside the IAM platform. The new features will integrate with tools from Salesforce (CRM), Microsoft's (MSFT) Copilot, and SAP (SAP) and will be deployed in the US starting in the middle of this year, the note said.RBC kept DocuSign's sector perform rating and $55 price target.Price: $49.02, Change: $+0.05, Percent Change: +0.10%

$DOCU
Wire

Haemonetics Likely to See Upside as Core Businesses Improve, BofA Securities Says

Haemonetics (HAE) is positioned for potential upside as the company has issued conservative fiscal 2027 guidance across its core segments Plasma, Hospital, and Blood Center, BofA Securities said in a note Friday.Analysts highlighted strong plasma collection trends, with US volumes rising high single digits in fiscal Q4, indicating potential upside if momentum continues.In the Hospital segment, the investment firm said vascular closure is improving with stronger commercial execution and blood management technologies are expected to remain a steady growth driver.Some upside is also likely in the Blood Center segment, where management has guided for a mid-single-digit decline, BofA said.Analysts cited potential catalysts, including Japan label expansion for vascular closure, the Japanese Red Cross plasma transition, possible tariff relief, and new products such as Vivasure's PerQseal Elite, with additional plasma innovation potentially supporting growth beyond 2027.BofA upgraded Haemonetics stock to buy from neutral, and raised its price target to $80 from $72.Shares of Haemonetics were up 2.7% in Friday trading.Price: $63.64, Change: $+1.70, Percent Change: +2.74%

$HAE
Wire

Imax's Potential Acquirers Include Private Equity Firms, Netflix, Apple, Sony, Wedbush Says

Imax (IMAX) is an "attractive" asset, and its most likely acquirers include private equity firms, Netflix (NFLX), Apple (AAPL), and Sony (SONY), Wedbush said in a Friday note.Imax is exploring a sale and has approached entertainment companies as potential buyers, the Wall Street Journal reported Thursday.At around $2 billion in enterprise value, Imax is trading below its standalone value and at a deeper discount as a potential acquisition target, the analysts said. They cited the company's well-known global brand, asset-light licensing model, and structurally expanding earnings profile.Private equity would be interested in Imax's free cash flow generation, minimal capital expenditure requirements relative to revenue, and a clear path to operational optimization. Ownership of Imax would also avoid any platform-conflict issue, the analysts said.Netflix ownership would not hamper rival studio access to the format as its content calendar is thin enough that purchasing Imax would not foreclose rival studio access to the format, according to the note.Netflix and Apple would also benefit from Imax becoming a powerful tool to woo major filmmakers, according to the note.Wedbush's rating on the company's stock is outperform with a price target of $46.Price: $38.77, Change: $+4.89, Percent Change: +14.43%

$AAPL$IMAX$NFLX$SONY